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Methods: This is a cross-sectional study of a consecutive co- 
hort of 110 patients with OA of the knee unresponsive to anti- 
inflammatory therapy who underwent arthroscopic debridement. 
The mean follow-up time was 34 months (range 24-74 months). 
The cohort consisted of 36 males and 74 females with an aver- 
age age of 61.7 years. Pain was assessed with the pain domain 
of the Knee Society scoring system. X-rays were scored by the 
Kellgren-Lawrence method, and limb alignment and medial and 
lateral joint space widths were measured. The severity of car- 
tilage lesions was scored intraoperatively by a modified Noyes 
grading system. Following grading, a standardized surgical de- 
bridement of damaged cartilage was performed. 
Results: Overall, 72/110 (65%) of patients had substantial pain 
relief post-operatively. The severity of pre-operative pain and the 
type of symptoms had no influence on postoperative pain scores. 
The severity of OA, as measured by the Kellgren-Lawrence score 
had a profound effect on outcome. 84% of knees with minimal 
radiographic hanges (grade 2) had substantial pain relief post- 
operatively, while only 25% of knees with severe OA (grade 4) 
experienced adequate pain relief. Of knees with moderate OA 
(grade 3) about one half (53%) experienced pain relief while an 
equal number were treatment failures. 85% of knees with a nor- 
mal tibiofemoral angle were considered treatment successes. A 
joint space width of 2mm or less was associated with poorer post- 
operative pain scores and a higher likelihood of treatment failure 
compared to knees with a joint space 3mm or greater. Lesion 
severity was also highly predictive of clinical outcome. 
Conclusions: A consensus on the usefulness of arthroscopy for 
OA of the knee has been elusive for 20 years. Most studies have 
aggregated outcome scores without regard to the extent of arthri- 
tis. We performed subgroup analysis to identify the knee char- 
acteristics, if any, that predicted symptomatic improvement. Our 
data revealed radiographic subsets of the population of knees 
with OA that can be associated with outcome after arthroscopic 
debridement. Still unresolved is the role of arthroscopy in the rel- 
atively large population of patients with moderate OA (Kellgren- 
Lawrence grade 3). For this group, cartilage lesion severity mea- 
sured intraoperatively was the only indicator of clinical outcome. 
Patients need to be counseled that their clinical outcome may 
depend upon the severity of cartilage lesions determined at 
surgery and their expectations of benefit need to take this into 
account. 
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To investigate parallel effects of a novel oral form of salmon cal- 
citonin (sCT) on bone resorption and cartilage degradation in el- 
derly women, and associations between rate of cartilage degra- 
dation, surrogate markers of osteoarthritis, and responsiveness 
to the pharmacodynamic effects of sCT. 
This was a randomized, double-blind, placebo-controlled clinical 
trial including 152 postmenopausal women. Participants received 
either sCT (0.15, 0.4, 1.0, 2.5 mg) combined with an Eligen ® 
technology-based carrier molecule (CNAC, 200 mg), or placebo 
for 3 months. The efficacy parameters were the changes in the 
24-hour urinary excretion of the C-telopeptide of collagen type II 
(CTX II; marker of cartilage degradation) and the C-telopeptide 
of collagen type I (CTX I; marker of bone resorption) from base- 
line at Month 3. Values were corrected for creatinine excretion. 
Personal interview collected information on joint symptoms, used 
medications, or joint replacements related to osteoarthritis. 
There were no differences between the different intervention 
groups in terms of age, BMI, and baseline measures of CTX I 
and II. At baseline, there was a weak correlation between mea- 
sures of CTX I and CTX II (R2=0.17, p<0.05), sCT induced dose- 
dependent decreases in the 24-hour urinary excretion of CTX 
II (p=0.002). Compared with baseline values, the inhibition was 
significant at the 0.4 mg dose and reached maximum at the 1.0 
mg dose (-19.7%, p=0.009). Similar pattern of changes was seen 
with CTX I. The maximal inhibition of CTX I excretion was seen 
at the 1.0 mg dose (-41.0%, p<0.001). There was a significant 
association between the 3-month changes in CTX I and CTX II 
(R2=0.33, p<0.001). In this population, 27% of women reported 
diagnosed OA or chronic joint pain. Women ih the highest CTX 
II tertile (3904-17 ng/mmol) reported joint symptoms and history 
of osteoarthroplasty more frequently compared with women in 
the lowest tertile (p<0.05). Furthermore, there were generally 
more pronounced decreases in CTX II to sCT in women belong- 
ing to the highest tertile of baseline CTX II. When focusing on 
subjects with high cartilage turnover at baseline, women who re- 
ceived treatment with 1.0 mg sCT showed statistically significant 
decreases compared with the effects of placebo (-30.6%, 95% 
CI -55.5 to -5.7%, p=0.01). 
The parallel decreases in CTX I and CTX II levels to sCT suggest 
that inhibition of bone turnover may confer favourable effects on 
cartilage turnover, but does not exclude the possibility of direct 
effects of sCT on chondrocytes. Based on these potential chon- 
droprotective ffects and the well-documented analgesic effects 
of calcitonin, further clinical assessment of this novel oral formula- 
tion as a candidate drug for the prevention of osteoarthritis eems 
warranted. 
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Objective: 1. To prove the efficacy over pain and function of 
Sodium hyaluronate and Chondroitin sulfate (HS/CS), blended in 
a gel, applied intraarticularly, vs. a Hylan G F 20 gel applied in- 
traarticularly, in the treatment of Osteoarthritis of the knee. 
2. To analyze the functional results using the proposed treatment. 
3. To determine the efficacy of the treatment using a visual analog 
scale (WOMAC). 
4. To report the final results. 
The trial used a group of 20 persons, 13 women and 7 men 
with ostheoarthritis grade II in the knee or patellar chondromala- 
sin. Men's age was 474-23.23 years (16 minimum, 80 maximum). 
Women's age was 60.54-16.02 years(30 minimum, 87 maximum). 
10 of them were treated with HS/CS and 10 with H G-F 20. They 
were evaluated at the beginning with Womac-index and with x- 
rays. They will be assigned to a treatment group to one of the 
following dosing regimens: a blend of 30 mg sodium hyaluronate 
and 40mg. chondroitin sodium sulfate/c.c. 1.5 c.c. every 15 days 
for 3 applications, 1.5 c.c. 90 days later and 1.5 c.c. 180 days af- 
ter that, or high molecular weight Hyaluronic Acid Hylane GF 20, 
8 mg./c.c. 2. c.c. every 8 days (3 applications) 2 c.c. 90 days later 
and 2 c.c. 180 days afterwards; both by intraarticular application 
at the knee, after aspiration of the existing synovial fluid and with 
an aseptic technique. 
